Protalix BioTherapeutics (PLX) Cash from Investing Activities (2010 - 2026)

Protalix BioTherapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 1453.53% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 51.96% YoY), while the FY2025 annual figure was -$2.4 million, down 156.05% from the prior year.
• Cash from Investing Activities was $4.2 million for Q1 2026 at Protalix BioTherapeutics, up from -$1.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $20.3 million in Q3 2024 to a low of -$20.9 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged -$921647.1 across 5 years, with a median of -$312000.0 in 2025.
• The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities slumped 4379.53% in 2024, then jumped 1453.53% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at $5.0 million in 2022, then sank by 106.9% to -$342000.0 in 2023, then plunged by 4379.53% to -$15.3 million in 2024, then soared by 92.74% to -$1.1 million in 2025, then soared by 479.77% to $4.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $4.2 million (Q1 2026), -$1.1 million (Q4 2025), and -$504000.0 (Q3 2025), per Business Quant data.